Intellia Therapeutics will present longer-term data from its ongoing Phase 1 trial of Nexiguran ziclumeran (Nex-Z), an investigational in vivo CRISPR/Cas9 therapy for hereditary ATTR amyloidosis with polyneuropathy, at the International ATTR Amyloidosis Meeting in Baveno, Italy, on September 25–26. The update will include disease-relevant measures with follow-up extending to three years, alongside a dedicated 24-month efficacy and safety readout. Nex-Z is designed as a one-time liver-directed edit to inactivate the TTR gene, aiming for deep and durable transthyretin reduction.
The strategic question is whether durable clinical benefit and clean safety at two to three years can catalyze the first regulatory pathway for an in vivo CRISPR therapy. Ex vivo CRISPR has already crossed the approval threshold, but in vivo editing still faces a proof bar that hinges on durability, off-target risk, and the translation of biomarker knockdown into functional outcomes. If the Baveno data move beyond TTR suppression to show sustained improvements on neurologic function and quality-of-life endpoints, the field shifts from “can we edit safely” to “how do we commercialize one-and-done editing in a market built for chronic therapy.”
For patients, a validated one-time option would mark a step-change from lifelong RNA silencing and TTR stabilization. For payers, it introduces an acute budget event in a rare disease with concentrated specialty centers and identifiable genotypes, where outcomes-based constructs and annuity models are more feasible than in diffuse common diseases. Health plans and HTA bodies will scrutinize not only absolute TTR lowering but also the magnitude and persistence of benefit on polyneuropathy progression versus today’s standards.
The competitive lens is unforgiving. Alnylam’s RNAi agents (patisiran, vutrisiran) and Ionis/AstraZeneca’s eplontersen have established efficacy and payer familiarity in ATTRv-PN, while tafamidis and next-generation stabilizers anchor cardiomyopathy. To break through, Nex-Z must demonstrate clinically meaningful and durable functional gains that justify irreversible editing over reversible suppression. If signals extend to cardiomyopathy cohorts over time, the commercial stakes climb sharply, given the larger ATTRwt and ATTR-CM populations. Conversely, any safety flags—hepatic, immunologic, or off-target—will slow not just this program but the broader in vivo editing category.
Medical Affairs teams should prepare for a different adoption curve. Irreversible editing will demand deeper consent processes, genetic counseling, and long-term monitoring frameworks that exceed typical rare-disease norms. Centers of excellence will likely lead early use, with registries and RWE programs becoming integral to payer negotiations and to post-approval commitments if the program advances. Education around patient selection, concomitant care needs, and management of potential class-specific risks will be decisive for uptake.
This readout also tests the evolving biotech playbook. Intellia’s collaboration with Regeneron illustrates how large-cap partners can de-risk first-in-class modalities while preserving speed in rare diseases. If the data support acceleration into a registrational path, expect renewed investor interest in in vivo editing platforms and a fresh round of portfolio realignments among companies anchored in chronic RNAi or small-molecule stabilizers.
All eyes now turn to Baveno: will the three-year view confirm that a single edit can durably change disease trajectory in ATTRv-PN and reset payer and HCP expectations for this category? The answer could define not only Intellia’s next move, but the commercial architecture for in vivo gene editing across specialty medicine.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
